Cutter & CO Brokerage Inc. Boosts Position in Heron Therapeutics, Inc. (NASDAQ:HRTX)

Cutter & CO Brokerage Inc. boosted its position in Heron Therapeutics, Inc. (NASDAQ:HRTX) by 69.6% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 33,135 shares of the biotechnology company’s stock after purchasing an additional 13,600 shares during the period. Cutter & CO Brokerage Inc.’s holdings in Heron Therapeutics were worth $51,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in HRTX. Clearline Capital LP lifted its stake in shares of Heron Therapeutics by 48.9% in the 3rd quarter. Clearline Capital LP now owns 2,226,512 shares of the biotechnology company’s stock worth $4,431,000 after purchasing an additional 731,246 shares during the period. Congress Park Capital LLC grew its position in Heron Therapeutics by 24.1% during the fourth quarter. Congress Park Capital LLC now owns 2,455,495 shares of the biotechnology company’s stock valued at $3,757,000 after buying an additional 477,417 shares during the period. XTX Topco Ltd increased its holdings in Heron Therapeutics by 449.0% during the third quarter. XTX Topco Ltd now owns 297,568 shares of the biotechnology company’s stock valued at $592,000 after buying an additional 243,363 shares during the last quarter. JPMorgan Chase & Co. raised its position in Heron Therapeutics by 295.8% in the third quarter. JPMorgan Chase & Co. now owns 206,711 shares of the biotechnology company’s stock worth $411,000 after acquiring an additional 154,487 shares during the period. Finally, BNP Paribas Financial Markets boosted its stake in shares of Heron Therapeutics by 50.4% during the 3rd quarter. BNP Paribas Financial Markets now owns 275,946 shares of the biotechnology company’s stock worth $549,000 after acquiring an additional 92,425 shares during the last quarter. 80.01% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

HRTX has been the subject of a number of recent research reports. Needham & Company LLC reissued a “buy” rating and set a $4.00 price objective on shares of Heron Therapeutics in a research report on Wednesday, December 4th. StockNews.com lowered Heron Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, January 29th.

Heron Therapeutics Trading Up 1.8 %

NASDAQ HRTX opened at $1.71 on Thursday. Heron Therapeutics, Inc. has a 12 month low of $1.04 and a 12 month high of $3.93. The stock has a market cap of $260.08 million, a price-to-earnings ratio of -9.50 and a beta of 1.60. The company’s 50 day moving average is $1.66 and its two-hundred day moving average is $1.71.

About Heron Therapeutics

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.